Industry
Biotechnology
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Loading...
Open
6.15
Mkt cap
182M
Volume
627K
High
6.24
P/E Ratio
-6.46
52-wk high
20.71
Low
5.72
Div yield
N/A
52-wk low
2.13
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 7:43 pm
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 3:39 pm
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 11:06 am
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 12:13 pm
Portfolio Pulse from Benzinga Newsdesk
July 01, 2024 | 2:13 pm
Portfolio Pulse from Benzinga Newsdesk
June 14, 2024 | 10:17 am
Portfolio Pulse from Benzinga Newsdesk
June 10, 2024 | 12:10 pm
Portfolio Pulse from Benzinga Newsdesk
June 07, 2024 | 5:24 pm
Portfolio Pulse from Benzinga Newsdesk
June 07, 2024 | 3:02 pm
Portfolio Pulse from Vandana Singh
June 06, 2024 | 1:52 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.